-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 14, the official website of CDE showed that Hebo Medicine and Kelun Botai declared HBM9378 injection (ie SKB378)
TSLP is one of the initiating factors of the inflammatory cascade.
In April 2018, Hebo Pharma and Kelun Botai reached a global strategic cooperation to jointly research, develop and commercialize new fully human antibody drugs
According to the Insight database, a total of 5 products with the same target are currently under research worldwide, of which 3 are developed by domestic companies
Global R&D Progress of Targeting TSLP Monoclonal Antibody Drugs
From: Insight database (http://db.
From the perspective of foreign progress, Novartis’ CSJ117 and Amgen/AstraZeneca’s Tezepelumab are in the late stages of clinical trials respectively, and Tezepelumab has also initiated phase III clinical trials in China